FLT3 and acute myeloid leukemia: Genetic abnormalities that involve internal tandem duplications or tyrosine kinase domain mutations in the FLT3 receptor gene (FLT3-ITD, FLT3-TKD) occur in ~30% of AML patients and are associated with poor prognosis and poor response to chemotherapy17,18.